ArticleBMJ oncology2025

Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF-mutant advanced melanoma: A matching-adjusted indirect comparison.

David M Miller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.